Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Impact of the MMR vaccine on the incidence of mumps in the Community of Madrid a...
Journal Information
Vol. 153. Issue 7.
Pages 276-280 (October 2019)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 153. Issue 7.
Pages 276-280 (October 2019)
Original article
Impact of the MMR vaccine on the incidence of mumps in the Community of Madrid and evaluation of the effectiveness of the Jeryl-Lynn strain. Years 1998–2016
Impacto de la vacuna triple vírica sobre la incidencia de la parotiditis en la Comunidad de Madrid y evaluación de la efectividad de la cepa Jeryl-Lynn entre 1998 y 2016
Visits
...
Pello Latasaa,
Corresponding author
latasa@salud.madrid.org

Corresponding author.
, María Ordobása, Macarena Garrido-Estepab, Juan Carlos Sanzc, Angel Gil de Migueld, Luis García-Comasa
a Subdirección General de Epidemiología, Dirección General de Salud Pública de la Comunidad de Madrid, Madrid, Spain
b Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain
c Laboratorio Regional de Salud Pública, Dirección General de Salud Pública de la Comunidad de Madrid, Madrid, Spain
d Departamento de Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (3)
Table 1. Vaccination strain administered in the Community of Madrid according to birth cohort.
Table 2. Cases and average annual incidence of mumps (cases per 100,000 inhabitants) by age group and period.
Table 3. Cases and average annual incidence of mumps (cases per 100,000 inhabitants) by birth cohorts and period.
Show moreShow less
Abstract
Introduction

Mumps is characterized by parotid inflammation and fever and is preventable by vaccination with MMR vaccine. The objective of the study is to assess the impact and effectiveness of the vaccine.

Material and methods

Cases notified to the Notifiable Disease System between 1998 and 2016 were used for the study. The vaccine effectiveness (VE) was calculated in cohorts vaccinated with two doses of Jeryl-Lynn, and the impact was calculated by comparing incidences by age and by Rubini (1995–1998) and Jeryl-Lynn (1999–2002) cohorts during the periods 1998–2004, 2005–2009 and 2010–2015. The incidences for age group and period were compared with the previous period and the incidences for cohorts were compared within a period with incidence ratios (IR) using Poisson models. The VE was estimated using the screening method using logistic regression models.

Results

13,816 cases were reported. The incidence in 2005–2009 was higher than in 1998–2004 (IR: 1.46, 95% CI: 1.40–1.53), and it remained stable in 2010–2015 (IR: 0.99, 95% CI: 0.95–1.03). The average incidence rate of the Rubini cohort was 69.43 and the Jeryl-Lynn cohort was 32.24. The IR was 0.25 (95% CI: 0.22–0.29), 0.55 (95% CI: 0.49–0.61) and 0.88 (95% CI: 0.76–1.00) for each period respectively. 2574 cases were included in the VE study. EV decreased over time reaching not significant values after seven years of follow-up (VE: 55%, 95% CI: 82 to −12%).

Conclusions

Parotiditis behavior is characterized by fluctuations, changes in presentation and a decrease in VE.

Keywords:
Mumps
Measles-mumps-rubella vaccine
Epidemiology
Effectiveness
Public health surveillance
Resumen
Introducción y objetivo

La parotiditis se caracteriza por la inflamación de la glándula parótida y fiebre, y es prevenible mediante vacunación con triple vírica (TV). El objetivo es evaluar el impacto y la efectividad vacunal (EV).

Material y métodos

Se seleccionaron los casos notificados al Sistema de Enfermedades de Declaración Obligatoria entre 1998 y 2016. La EV se calculó en cohortes vacunadas con 2 dosis de Jeryl-Lynn, y el impacto comparando las incidencias por edad y por cohortes Rubini (1995-1998) y Jeryl-Lynn (1999-2002) en los periodos 1998-2004, 2005-2009 y 2010-2015. Las estimaciones por grupo de edad y período se compararon con las del período anterior y las estimaciones por cohortes se compararon entre sí dentro de cada período mediante razones de incidencia (RI) empleando modelos de Poisson. La EV se estimó empleando el método de cribado mediante modelos de regresión logística.

Resultados

Se notificaron 13.816 casos. La incidencia en 2005-2009 fue superior a la de 1998-2004 (RI: 1,46; IC 95%: 1,40-1,53), y en 2010-2015 se mantuvo estable (RI: 0,99; IC 95%: 0,95-1,03). La incidencia anual media de las cohortes Rubini fue de 69,43 casos por 100.000 habitantes y la de las cohortes Jeryl-Lynn de 32,24. La RI fue de 0,25 (IC 95%: 0,22-0,29), 0,55 (IC 95%: 0,49-0,61) y 0,88 (IC 95%: 0,76-1,00) para cada periodo, respectivamente. Se incluyeron 2.574 casos en el estudio de EV. La EV disminuyó con el tiempo al alcanzar valores no significativos tras 7 años de seguimiento (EV: 55%; IC 95%: 82 a -12%).

Conclusiones

El comportamiento de la parotiditis se caracteriza por presentar fluctuaciones, cambios en la presentación etaria y una disminución de la EV.

Palabras clave:
Paperas
Vacuna contra el sarampión-parotiditis-rubéola
Epidemiología
Efectividad
Vigilancia en salud pública

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos